Evaluating impact of school outreach vaccination programme in Hong Kong influenza season 2018 - 2019.

School-based vaccination, as a means to mitigate seasonal influenza outbreak, depends on attaining adequate coverage rate. We evaluated the potential of a fully subsidized school outreach vaccination (SOV) program to achieve epidemic prevention potential in Hong Kong. The purpose of this study was to evaluate the impact of SOV program 2018-2019 on influenza vaccination rates and influenza-like illness (ILI) in the primary school students and their household members during the influenza season. The vaccination rate was significantly higher in the schools offering SOV (intervention schools) (69.2% vs. 34.3%) than those not offering SOV (control schools) (p < .0001). The ILI rate was significantly reduced from 14.1% among non-vaccinated to 7.7% among vaccinated students (p < .0001). Influenza vaccine effectiveness against ILI was 45.3%. The vaccination rates of the household members were the same in both intervention and control schools except in the sub-group of preschool household members with the intervention significantly higher than the control group (43.8% vs. 32%, p < .0001). SOV program significantly improved influenza vaccine coverage, and the vaccine reduced ILI incidence. Extension of SOV program to all primary schools as well as kindergartens in Hong Kong could achieve epidemic prevention potential and should be evaluated.

Vitamin D Deficiency and Effects of Vitamin D Supplementation on Disease Severity in Patients with Atopic Dermatitis: A Systematic Review and Meta-Analysis in Adults and Children.

Research has investigated 25-hydroxyvitamin D (25(OH)D) levels in the Atopic Dermatitis (AD) population, as well as changes in AD severity after vitamin D (VitD) supplementation. We performed an up-to-date systematic review and meta-analysis of these findings. Electronic searches of MEDLINE, EMBASE and COCHRANE up to February 2018 were performed. Observational studies comparing 25(OH)D between AD patients and controls, as well as trials documenting baseline serum 25(OH)D levels and clinical severity by either SCORAD/EASI scores, were included. Of the 1085 articles retrieved, sixteen were included. A meta-analysis of eleven studies of AD patients vs. healthy controls (HC) found a mean difference of -14 nmol/L (95% CI -25 to -2) for all studies and -16 nmol/L (95% CI -31 to -1) for the paediatric studies alone. A meta-analysis of three VitD supplementation trials found lower SCORAD by -11 points (95% CI -13 to -9, p < 0.00001). This surpasses the Minimal Clinical Important Difference for AD of 9.0 points (by 22%). There were greater improvements in trials lasting three months and the mean weighted dose of all trials was 1500-1600 IU/daily. Overall, the AD population, especially the paediatric subset, may be at high-risk for lower serum 25(OH)D. Supplementation with around 1600 IU/daily results in a clinically meaningful AD severity reduction.